217 related articles for article (PubMed ID: 29324537)
1. The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.
Tajik P; van de Vrie R; Zafarmand MH; Coens C; Buist MR; Vergote I; Bossuyt PMM; Kenter GG
Int J Gynecol Cancer; 2018 Mar; 28(3):453-458. PubMed ID: 29324537
[TBL] [Abstract][Full Text] [Related]
2. Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer.
Sørensen SM; Høgdall C; Mosgaard BJ; Dalgaard MIR; Jensen MP; Fuglsang K; Schnack TH
Acta Obstet Gynecol Scand; 2022 Mar; 101(3):334-343. PubMed ID: 35187660
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study.
Gao Y; Li Y; Zhang C; Han J; Liang H; Zhang K; Guo H
J Ovarian Res; 2019 Sep; 12(1):85. PubMed ID: 31519183
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer.
Liu H; Luo M; Peng C; Huang J; Wang D; Huang J; Zhang G
Front Oncol; 2023; 13():1103357. PubMed ID: 37564940
[TBL] [Abstract][Full Text] [Related]
5. Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.
Lee J; Curtin JP; Muggia FM; Pothuri B; Boyd LR; Blank SV
Cancer Chemother Pharmacol; 2018 Jul; 82(1):55-63. PubMed ID: 29704010
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract][Full Text] [Related]
7. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
[TBL] [Abstract][Full Text] [Related]
8. The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
Ataseven B; Harter P; Grimm C; Heitz F; Heikaus S; Traut A; Kahl A; Kurzeder C; Prader S; du Bois A
Gynecol Oncol; 2016 Aug; 142(2):243-7. PubMed ID: 27208538
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
[TBL] [Abstract][Full Text] [Related]
10. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
[TBL] [Abstract][Full Text] [Related]
11. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.
Wang D; Zhang G; Peng C; Shi Y; Shi X
J Ovarian Res; 2021 Mar; 14(1):49. PubMed ID: 33771198
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of the subclassification of Müllerian cancer stage IV in the FIGO 2014 staging system with a focus of extra-abdominal lymph node metastases.
Yasunaga M; Yahata H; Okugawa K; Hori E; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K
Int J Clin Oncol; 2021 Jul; 26(7):1330-1335. PubMed ID: 33786711
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
14. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI
Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626
[TBL] [Abstract][Full Text] [Related]
15. A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer.
Métairie M; Benoit L; Koual M; Bentivegna E; Wohrer H; Bolze PA; Kerbage Y; Raimond E; Akladios C; Carcopino X; Canlorbe G; Uzan J; Lavoué V; Mimoun C; Huchon C; Koskas M; Costaz H; Margueritte F; Dabi Y; Touboul C; Bendifallah S; Ouldamer L; Delanoy N; Nguyen-Xuan HT; Bats AS; Azaïs H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765667
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
[TBL] [Abstract][Full Text] [Related]
18. Metastatic patterns do not provide additional prognostic information for patients with FIGO stage IV high-grade serous ovarian cancer.
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
J Surg Oncol; 2020 Aug; 122(2):315-319. PubMed ID: 32500598
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy.
Michaan N; Chong WY; Han NY; Lim MC; Park SY
Int J Gynecol Cancer; 2018 Nov; 28(9):1676-1682. PubMed ID: 30256239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]